Sources of Long-Term Quality Adjusted Life Year (QALY) Gains for Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting

Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.681
https://www.valueinhealthjournal.com/article/S1098-3015(13)02586-2/fulltext
Title : Sources of Long-Term Quality Adjusted Life Year (QALY) Gains for Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02586-2&doi=10.1016/j.jval.2013.08.681
First page : A441
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 655
Categories :
Tags :
Regions :
ViH Article Tags :